Emergence of tet (X2) in Acinetobacter pittii confers clinical resistance to tigecycline
Journal of Antimicrobial Chemotherapy · 01.06.2023 · 78 (6) · 1543-1546
DOI: 10.1093/jac/dkad133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.05.2023. Verfasst von Changrui Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Clinical Laboratory Diagnosis and T…. Hauptthemen laut MEDLINE: Acinetobacter, Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Key Laboratory of Clinical Laboratory Diagnosis, Translational Research of Zhejiang Province.
Abstract (Originalsprache)
Objectives
To characterize a novel transposon Tn7533 carrying the tet(X2) gene in a tigecycline-resistant Acinetobacter pittii BM4623 of clinical origin.
Methods
Gene knockout and in vitro cloning were used to verify the function of tet(X2). WGS and comparative genomic analysis were used to explore the genetic characteristics and molecular evolution of tet(X2). Inverse PCR and electroporation experiments were used to evaluate the excision and integration capabilities of Tn7533.
Results
A. pittii BM4623 belonged to a novel ST, ST2232 (Pasteur scheme). Knockout of tet(X2) in BM4623 restored its susceptibility to tigecycline. Cloning of the tet(X2) gene into Escherichia coli DH5α and Acinetobacter baumannii ATCC 17978 resulted in 16-fold or more increases in MICs of tigecycline. Sequence analysis showed that the region upstream of tet(X2) exhibited a high degree of diversity, while there was a 145 bp conserved region downstream of tet(X2). tet(X2) in BM4623 was located on a novel composite transposon Tn7533, which also contains multiple resistance genes including blaOXA-58. Tn7533 could be excised from the chromosome to form a circular intermediate and transferred into A. baumannii ATCC 17978 by electroporation.
Conclusions
Our study demonstrates that tet(X2) is a determinant conferring clinical resistance to tigecycline in Acinetobacter species. The emergence of Tn7533 may lead to the potential dissemination of tigecycline and carbapenem resistance in Acinetobacter, which requires continuous monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang Province…
- School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
ORCID-Profile: Tieli Zhou
Förderung
- Key Laboratory of Clinical Laboratory Diagnosis
- Translational Research of Zhejiang Province
Zitieren
APA
Qian, C., Ma, Z., Feng, L., Guo, W., Han, Y., Zhang, Y., Xu, C., Cao, J., & Zhou, T. (2023). Emergence of tet (X2) in Acinetobacter pittii confers clinical resistance to tigecycline. Journal of Antimicrobial Chemotherapy, 78(6), 1543-1546. https://doi.org/10.1093/jac/dkad133
Vancouver
Qian C, Ma Z, Feng L, Guo W, Han Y, Zhang Y, et al. Emergence of tet (X2) in Acinetobacter pittii confers clinical resistance to tigecycline. Journal of Antimicrobial Chemotherapy. 2023;78(6):1543-1546. doi:10.1093/jac/dkad133
BibTeX
@article{Qian2023,
author = {Qian, Changrui and Ma, Zhexiao and Feng, Luozhu and Guo, Wenhui and Han, Yijia and Zhang, Yi and Xu, Chunquan and Cao, Jianming and Zhou, Tieli},
title = {Emergence of tet (X2) in Acinetobacter pittii confers clinical resistance to tigecycline},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {6},
pages = {1543--1546},
doi = {10.1093/jac/dkad133}
}
EUVIMED